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Abstract
Objective: The search for genetic vulnerability factors in cocaine dependence has focused on the role that neuroplasticity
plays in addiction. However, like many other drugs, the ability of an individual to metabolize cocaine can also influence
susceptibility to dependence. Butyrylcholinesterase (BChE) metabolizes cocaine, and genetic variants of the BChE gene
(BCHE) alter its catalytic activity. Therefore, we hypothesize that cocaine users with polymorphisms in BCHE can show
diverse addictive behaviors due to differences in effective plasma concentrations of cocaine. Those polymorphisms might
also influence users to prefer one of the two main preparations (crack or powder cocaine), despite having equal access to
both. The present work investigates polymorphisms in BCHE and if those genetic variants constitute risk factors for cocaine
dependence and for crack cocaine use.
Methods: A total of 1,436 individuals (698 cocaine-dependent patients and 738 controls) were genotyped for three single
nucleotide polymorphisms (SNPs) in BCHE: rs1803274, rs4263329, and rs4680662.
Results: For rs4263329, a nominal difference was found between cases and controls. For rs1803274 (the functional SNP), a
statistically significant difference was found between patients who used crack cocaine exclusively and those who used only
powder cocaine (P = 0.027; OR= 4.36; 95% CI = 1.18–16.04). Allele frequencies and genotypes related to other markers did
not differ between cases and controls or between the two cocaine subgroups.
Conclusions: Our findings suggest that the AA genotype of rs1803274 is a risk factor for crack cocaine use, which is more
addictive than powder cocaine use. Further studies are needed in order to confirm this preliminary result and clarify the role
of BCHE and its variants in cocaine dependence.
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Introduction
Cocaine addiction is a complex behaviour that arises from the
interactions between genetic and environmental risk factors. Twin
studies indicate that the heritability of cocaine addiction is
approximately 60% and fits a complex polygenic model [1].
Cocaine binds strongly to the dopamine transporter, and this
blockade of dopamine reuptake is perhaps the key mechanism
leading to cocaine addiction [2]. In fact, some studies have already
reported genetic markers in dopaminergic brain systems associated
with cocaine dependence [3–5]. However, many of those markers
are also associated with other psychiatric disorders or substance-
related disorders other than cocaine-related disorders and
therefore might not be specific markers for the cocaine depen-
dency risk [6–8]. The results of twin studies indicate that the
heritability of substance dependence can be general or drug-
specific, suggesting that specific genetic markers increase suscep-
tibility to dependence on distinct drugs [9,10]. In one of the largest
studies of cocaine dependence to date [3] various polymorphisms
were found to be associated with the cocaine-dependent pheno-
type, as has also been demonstrated in animal studies involving
markers related to the dopaminergic reward system and to other
biochemical pathways [11,12].
Although cocaine users use the drug in various forms, most can
be distinguished by their preferred route of cocaine administration:
inhalation (smoking crack cocaine); nasal (snorting powder
cocaine); or injection (injecting a cocaine preparation) [13]. Those
subgroups have been associated with specific characteristics of
cocaine use: escalation of consumption; degree of abuse liability;
propensity for dependence; and treatment response [14,15]. It is
argued that the reinforcing effect of smoked (crack) cocaine is
greater than is that of snorted (powder) cocaine because, when the
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drug is smoked, the peak effect is achieved more quickly and
concentrations of the drug in the central nervous system are higher
for an equivalent amount of cocaine consumed [16]. Nevertheless,
most cocaine-dependent patients have a preferred route of
administration, despite having been exposed to both forms [13].
Therefore, the preferred route of administration can represent a
distinct phenotype among cocaine users and should be taken into
account when investigating individual genetic susceptibility to
cocaine use and abuse.
One limitation of previous studies on genetic susceptibility to
cocaine dependence, as well as to other complex disorders, is that
known polymorphisms may explain only a small fraction of the
heritability variance in cocaine dependence. Therefore, there is a
need for studies investigating putative additional genetic markers
associated with susceptibility to cocaine dependence, in particular
those that might be specific to this disorder [17].
Pharmacogenetic factors, especially genetic aspects that modu-
late the plasma concentration of cocaine, could play a role in
cocaine susceptibility and have yet to be studied. Once absorbed,
cocaine is rapidly transformed in two main metabolites, benzoy-
lecgonine and ecgonine methyl ester, both of which are
pharmacologically inactive [18]. The hydrolysis that leads to the
formation of ecgonine methyl ester is catalyzed by butyrylcholi-
nesterase (BChE), which is an enzyme involved in the metabolism
of certain drugs (including cocaine and heroin), various local
anesthetics, and short-acting muscle relaxants [19]. BChE is
synthesized primarily in the liver and is distributed throughout the
intestinal mucosa, in plasma, and in the white matter of the central
nervous system [20]. The enzyme is encoded by the BChE gene
(BCHE), which is located on chromosome 3q26 [21]. The BCHE
genomic region spans approximately 70 kb, with four exons and
three large introns [22]. Although more than 65 BCHE mutations
have been identified, not all of them have been fully studied [23].
In general, these mutations produce enzymes with lower levels of
catalytic activity than that of those produced by wild-type
mutations [24]. BChE has also been tested as a novel therapeutic
agent for cocaine dependence: a quadruple mutant hydrolase
derived from human BChE suppressed cocaine toxicity and
abolished drug-primed reinstatement in rats [25]. Our working
hypothesis is that polymorphisms in BCHE lead to various enzyme
profiles that allow different concentrations of cocaine to reach the
reward system in the brain, thereby increasing or decreasing
susceptibility to developing addictive behaviors.
The objective of this study is to identify genetic variations in
BCHE as risk factors for dependence in patients whose primary
drug of abuse is cocaine. We also investigate those genetic markers
and the preferred route of cocaine administration for any existing
correlation.
Methods
The patient sample consisted of 698 cocaine-dependent patients
[mean age 26.867.2 years; 96% males (n = 669)], recruited and
evaluated as inpatients and outpatients from seven drug depen-
dence treatment clinics in Sa˜o Paulo, Brazil. All of the patients met
the criteria for cocaine dependence established in the tenth
revision of the International Classification of Diseases. At
enrollment, each patient was subjected to a screening interview,
designed specifically for use in Brazil, that included questions
related to sociodemographic variables and to drug use [26].
We recruited 738 unrelated controls [mean age 31.369.8 years
and 68% males (n = 501)] from the Fundac¸a˜o Pro´-Sangue,
Hospital das Clı´nicas, Universidade de Sa˜o Paulo (Blood Donation
Center at the University of Sa˜o Paulo School of Medicine).
Exclusion criteria were: those with a history of drug abuse or
recent use of illicit drugs, as were those with a history of psychiatric
inpatient treatment or with a current psychiatric condition.
To conduct a comparative analysis according to the route of
cocaine administration, we divided the patient sample into three
subgroups: those who reported using only powder cocaine
(typically by snorting); those who reported using only freebase
cocaine hydrochloride (crack cocaine) which is smoked in small
pipes and, those who reported using both routes of cocaine
administration (dual users). A detailed description of the above
subgroups can be found elsewhere [13].
Ethics Statement
The study was approved by the Comissa˜o de E´tica para a
Ana´lise de Projeto de Pesquisa (CAPPesq, Ethics Committee for
the Analysis of Research Projects) of the University of Sa˜o Paulo
School of Medicine. All participants provided written informed
consent.
Genotyping
All of the participants were genotyped for three single
nucleotide polymorphisms (SNPs) in BCHE: rs1803274,
rs4263329, and rs4680662. To that end, blood samples were
collected in tubes containing ethylenediaminetetraacetic acid, and
genomic DNA was extracted by standard methods.
The SNP rs1803274 was selected because it is a common
variant, known as the K variant, that leads to a functional decrease
in BChE activity [24]. The other two SNPs were selected on the
basis of the linkage disequilibrium (LD) structure of the gene, allele
frequency, and available Haplotype Map data (http://hapmap.
ncbi.nlm.nih.gov/index.html.en). Genotyping was conducted by
Prevention Genetics (Marshfield, Wisconsin, USA; http://www.
preventiongenetics.com/). For all genotypes, the Hardy-Weinberg
equilibrium was assessed using the Haploview software, version 4.2
[27]. To estimate the statistical power of the sample, we used the
QUANTO program, version 1.2, assuming an odds ratio (OR) of
1.5, a disease prevalence of 0.03, a calculated average minor allele
frequency of 0.27, and a significance level of 0.05 [28].
We performed principal component analysis (PCA) to assess
allele frequency differences between cases and controls due to
ancestry differences and statistical analyses were performed using
EIGENSTRAT [29,30]. This software detects population struc-
ture inferring axes of genetic variation and outputs each
individual’s coordinates along axes of variation. The analysis was
performed using a panel of 64 SNPs ancestry-informative markers
(AIMs) and models were created with two to five principal
components in order to detect the existence or absence of
population structure; details of marker set are available on request.
In our data set, we were not able to demonstrate a difference in
population stratification between cases and controls therefore, no
corrections using the PCA results were done in the association tests
for the BCHE markers (Figure 1).
A general test of association (the two-degree-of-freedom test of
genotypic association) was applied, and three individual contrasts,
defined by a priori genetic models (additive, dominant, and
recessive), were computed. In the dominant and recessive models,
explanatory variables were binary. We employed logistic regres-
sion to adjust for age and sex. No statistical correction was made
for multiple comparisons in the general test of association. The LD
and the haplotype frequencies were estimated with the Haploview
software, version 4.2. Haplotype blocks were identified using the
solid spine of LD method in Haploview and correction for multiple
testing was performed using permutation correction by the
Haploview program [27]. Chi-square values, ORs, and 95%
BCHE Genetic Variants and Cocaine Dependence
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confidence intervals (95% CIs) were estimated using the Statistical
Package for the Social Sciences, version 17.0 (SPSS Inc., Chicago,
Illinois, USA).
Results
The socio-demographic and clinical characteristics of the
participants are summarized in Table 1. The patient and control
groups differed significantly in terms of sex and age. Most of the
patients used cannabis and were cigarette smokers. Roughly half of
the patients ingested more than 50 units of alcohol per week and
had been in prison at least once. In terms of the preferred route of
cocaine administration, 23% of the participants reported using the
nasal route (snorting powder cocaine) exclusively, 9% reported
using the inhalation route (smoking crack cocaine) exclusively, and
68% reported using both routes concurrently (dual users). For
cases and controls, none of the allele distributions deviated
significantly from those expected on the basis of the Hardy-
Weinberg equilibrium (Table 2). When we adopted a recessive
model of transmission, the GG genotype of rs4263329 was less
common in cases than in controls [f(GG) = 1.2% vs. f(GG) = 2.6%;
OR 2.3, 95% CI = 0.99–5.32]. After adjustment for age and sex,
that association was no longer significant (P.0.1). As can be seen
in Table 2, genotypes of the two other markers did not differ
between cases and controls, nor did the allele frequencies of the
three markers. Measures of LD and haplotype blocks across
BCHE did not produce any evidence for an association with
disease (data not shown). Results of the general tests of association
for the preferred route of cocaine administration can be seen in
Table 3. Of the three markers, only rs1803274 was associated with
distinct genotypes among the subgroups of cocaine users. Among
the a priori genetic models, the recessive model (genotype AA) best
accounted for the significant difference between crack users and
powder cocaine users (P = 0.027; OR = 4.36; 95% CI = 1.18–
16.04), as well as for that observed between crack users and dual
users (P = 0.001; OR = 5.83; 95% CI = 2.10–16.16). Those asso-
ciations remained significant after adjustment for age and sex (data
not shown).
Discussion
We evaluated the distribution of three SNPs in BCHE in a
sample of cocaine-dependent patients and controls in Brazil. For
the SNP rs4263329, there was a nominal association between
patients and controls [GG genotype, P = 0.05, OR = 2.3; 95%
CI = 0.99–5.32]. We also found a significant association between
rs1803274 and crack cocaine (AA genotype) as the preferred route
of administration (p,0,005). To our knowledge, this is the only
report in the literature investigating BCHE variants and crack/
cocaine.
We are aware that these results could be false positive ones, but
in order to minimize the likelihood of it, we used the best available
methodology and analysis. Firstly, the investigated sample is one of
the largest samples of crack/cocaine patients reported in the
Figure 1. Population Structure Analysis. Graphic representation of the first two principal components for cases and controls genotyped with 64
AIMs, each point in this plot is an individual. The distribution of individuals in the axes is similar for both groups therefore the EIGENSTRAT software
was not able to detect a difference in population stratification between cases and controls.
doi:10.1371/journal.pone.0080505.g001
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literature to study genetic susceptibility for cocaine dependence to
date. We also adjusted for confounding factors (age and sex) to
confirm that the association was not due to bias. Population
stratification was tested with the EIGENSTRAT software and no
differences were observed between cases and controls which could
hinder the association results. In contrast with other studies
investigating the association of genetic markers and cocaine
dependence [31,32], subjects in the present study were stratified by
Table 1. Characteristics of cocaine-dependent patients
and control subjects.
Characteristic Patients Controls
(n =698) (n =738)
Age, in years, mean 6 SD (range) 26.867.2 (17–56) 31.369.8 (18–72)
Sex
Male, n (%) 669 (95.8) 501 (67.9)
Female, n (%) 29 (4.2) 237 (32.1)
Preferred route of administration
Nasal (powder cocaine users), n (%) 160 (22.9)
Inhalation (crack cocaine users), n (%) 61 (8.7)
Either (dual users), n (%) 477 (68.3)
Cigarette smoking
Yes, n (%) 585 (83.8)
No, n (%) 111 (15.9)
Alcohol consumption
,50 units/week, n (%) 417 (59.7)
.50 units/week, n (%) 247 (35.4)
None, n (%) 34 (4.8)
History of cannabis use
Yes, n (%) 666 (95.4)
No, n (%) 23 (3.3)
No data, n (%) 9 (1.3)
Criminal history
Yes, n (%) 373 (53.4)
No, n (%) 324 (46.4)
No data, n (%) 1 (0.1)
SD, standard deviation.
doi:10.1371/journal.pone.0080505.t001
Table 2. Genotype and allele frequencies of three
BCHE markers in cocaine-dependent patients and
controls.
Genotype Allele HWE (P)
SNP/Group AA AG GG n G A
rs1803274
Patients, n (%) 18 (2.7) 201
(29.7)
457
(67.6)
676 0.82 0.18 1.0
Controls, n (%) 30 (4.2) 215
(29.8)
477
(66.1)
722
rs4263329a
Patients, n (%) 497
(72.6)
180
(26.3)
8 (1.2) 685 0.14 0.86 1.0
Controls, n (%) 538
(74.5)
165
(22.9)
19 (2.6) 722
rs4680662
Patients, n (%) 75 (10.9) 317
(46.0)
297
(43.1)
689 0.66 0.34 0.71
Controls, n (%) 81 (11.6) 316
(45.1)
303
(43.3)
700
SNP, single nucleotide polymorphism; HWE, Hardy-Weinberg equilibrium.
ars4263329 GG genotype, P = 0.052, odds ratio = 2.3 (95% confidence
interval = 0.99–5.32).
doi:10.1371/journal.pone.0080505.t002
Table 3. Genotype frequencies of three BCHE markers in cocaine-dependent patients, by preferred form of cocaine
administration.
Genotype n x2 P
SNP/Subgroup AA AG GG
rs1803274a
Powder cocaine users, n (%) 4 (2.6) 45 (29.0) 106 (68.4) 155
Crack users, n (%) 6 (10.6) 14 (24.1) 38 (65.5) 58
Dual users, n (%) 8 (1.7) 142 (30.7) 313 (67.6) 463
Total, n (%) 18 (2.7) 201 (29.7) 457 (67.6) 676 15.20 0.004
rs4680662
Powder cocaine users, n (%) 16 (10.1) 77 (48.7) 65 (41.1) 158
Crack users, n (%) 4 (6.6) 29 (47.5) 28 (45.9) 61
Dual users, n (%) 55 (11.7) 211 (44.9) 204 (43.4) 470
Total, n (%) 75 (10.9) 317 (46.0) 297 (43.1) 689 2.10 0.718
rs4263329
Powder cocaine users, n (%) 107 (68.2) 46 (29.3) 4 (2.5) 157
Crack users, n (%) 46 (76.7) 13 (21.7) 1 (1.7) 60
Dual users, n (%) 344 (73.5) 121 (25.9) 3 (0.6) 468
Total, n (%) 497 (72.6) 180 (26.3) 8 (1.2) 685 5.48 0.241
ars1803274 AA genotype, P = 0.027; OR = 4.36 (95% confidence interval = 1.18–16.04), between crack users and powder users.
doi:10.1371/journal.pone.0080505.t003
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their preferred route of drug administration. This may decrease
the sample’s clinical heterogeneity, which frequently reduces the
power of genetic association studies. Another confounding factor
in previous studies was a concomitant dependence on other drugs,
mainly alcohol and heroin. In the present study, individuals with
alcohol dependence were excluded, and heroin dependence is very
rare in Brazil (less than 1% of our sample used heroin). This
attempt to make the sample more homogeneous may strengthen
the specificity of any genetic association found as related to the
condition of cocaine use per se. From a statistical standpoint, our
sample had a power of 88% of detecting true associations.
One of the markers investigated in our study, rs1803274, was
not associated with cocaine dependence but was associated with
crack smoking as the preferred route of administration. Although
the rs1803274 marker has previously been shown to be associated
with behavioral and medical conditions [33,34], we found no
studies investigating the role of rs1803274 in substance depen-
dence or other substance-related psychiatric disorders to date. The
fact that we found an association only when the sample was
divided into subgroups is not unique. An association with a genetic
marker in cocaine dependence was found when the sample was
subdivided into those who had experienced psychotic symptoms
during episodes of cocaine intoxication and those who had not
[35]. Because cocaine dependent subjects constitute a heteroge-
neous group not only from a genetic standpoint but also from a
clinical perspective, it is useful to study them in meaningful
subgroups. Dual users have distinct clinical features that distin-
guish them from those who are exclusive users of crack or snorted
cocaine [13]. In the present study, allele frequencies for rs1803274
were very similar to the values for the Haplotype Map population
of Utah residents with ancestry from northern and western Europe
(CEU population). We also found that the frequency of the AA
genotype in our sample as a whole was greater than in the CEU
population (3.3% compared to 1.7%). The other two markers
investigated have been infrequently used in association studies.
Twelve BCHE SNPs were tested in farmers exposed to
organophosphates and rs4680663 was not found to be associated
with cholinesterase activity [36]. We found no association studies
using the SNP rs4263329 as a marker.
Common variants have been associated with altered cholines-
terase activity in samples drawn from the community [36]. The
SNP rs1803274 is a common variant in BCHE, and the A allele
leads to a point mutation at nucleotide 1615 that changes codon
539 from GCA (ala) to ACA (thr) [38]. In carriers of the A allele,
serum BChE levels are reduced by 30%. Decreased BChE activity
increase the amount of cocaine that reaches the reinforcing brain
areas, thereby augmenting its propensity to lead to dependence.
Most cocaine users in Brazil have equal access to crack and
powder cocaine, and the AA genotype can, in part, explain the fact
that some users prefer to use crack cocaine exclusively. It is likely
that the enzymatic changes interact with other known predisposing
factors for crack dependence and account for part of the genetic
vulnerability to this route of administration.
Like any genetic association study, our study has limitations that
must be addressed. First, although we found a nominal association
between rs4263329 and cocaine dependence, that association lost
its significance after being adjusted for sex and age. Nevertheless,
that is an interesting finding that warrants further studies in
comparable populations. Second, our sample size, although large
for this particular line of research, could be considered small for a
genetic association study looking for a susceptibility gene with a
small magnitude effect. Third, although the marker reported here
to be associated with exclusive crack cocaine use has been
correlated with functional enzymatic alterations in other studies,
we did not obtain any cholinesterase measures, which would have
allowed us to make a functional correlation between carrying the
marker and its function in patients and controls [23,36]. By the
same token, we had no objective parameters of cocaine use in
cases and controls, such as toxicological measurements of cocaine
in hair or urine. The subjective ratings reported by cocaine users
are known to be unreliable markers of the true amount and
frequency of illegal substance use, and that holds true for self-
reported drug use by non-dependent subjects, such as our controls
[37]. Although we consider it unlikely, it is possible that our
controls underreported cocaine use and dependence, which would
have decreased the strength of the association found in the present
study. Finally, it is possible that the BCHE SNP that is associated
with vulnerability to crack use is not the actual causative SNP;
instead, other nearby SNPs in LD could be the alternative
causation.
Although some investigators have identified genetic components
of susceptibility to cocaine dependence, only a small portion of the
heritability is explained by those findings [17]. So many of the
genetic susceptibility makers or genetic mechanisms for crack/
cocaine dependence are still unknown. The identification of these
new genetic markers will contribute to prevent and to treat drug
abuse/dependent patients. In the present study, we evaluated
three SNPs in BCHE, all of which are potentially involved in
cocaine metabolism. Although we did not find an association
between those markers and cocaine dependence per se, we
observed an association between the known functional genotype
(the K variant) and a preference for the inhalation (crack smoking)
route of cocaine administration. Further studies involving a
replication in other independent case-control samples and/or
investigation involving a correlation between the function and the
genetic variants and/or sequencing of this region would be very
welcome to clarify the preliminary findings of the present report.
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